Scienza e Tecnologia
Alzinova completes humanisation work and selects lead candidate for monoclonal antibody ALZ-201
Anders Sandberg , at Alzinova, says, "The antibody ALZ-201 has a unique binding profile and strong preclinical efficacy data. That it now has been engineered to be tolerated by humans enables its further development as a potential therapeutic to treat Alzheimer's patients. We believe that this antibody and the related vaccine, ALZ-101, can potentially make a huge difference for the future of Alzheimer's disease treatments."
In December 2021 , Alzinova communicated the results from a research collaboration with Amsterdam University Medical Centers. Data from the project confirmed the unique specificity and preclinical efficacy of ALZ-201.
The humanised monoclonal antibody, ALZ-201, has the potential to be developed as a novel therapy to specifically target toxic forms of the amyloid beta peptide (oligomers), and thus prevent its neurotoxic effect on neurons. Aggregation of the amyloid beta in the brain is widely recognized as a main driver of Alzheimer's disease.
Both ALZ-201 and the related therapeutic vaccine, ALZ-101, which is in clinical development, are novel immunotherapies with very specific and targeted effects, which could translate to more favorable clinical profiles with best-in-class potential compared to other amyloid beta-targeting immunotherapies.
The company plans to communicate more details on the future development of ALZ-201 during the first half of 2022.
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/alzinova/r/alzinova-completes-humanisation-work-and-selects-lead-candidate-for-monoclonal-antibody-alz-201,c3489745
The following files are available for download: